Quanterix (NASDAQ: QTRX) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.
Valuation and Earnings
This table compares Quanterix and Pacific Biosciences of California’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Quanterix||$22.87 million||15.29||-$27.01 million||($8.30)||-1.92|
|Pacific Biosciences of California||$93.47 million||5.46||-$92.18 million||($0.87)||-4.45|
This is a breakdown of recent ratings and price targets for Quanterix and Pacific Biosciences of California, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pacific Biosciences of California||0||2||0||0||2.00|
Quanterix currently has a consensus price target of $26.50, indicating a potential upside of 66.46%. Pacific Biosciences of California has a consensus price target of $5.40, indicating a potential upside of 39.53%. Given Quanterix’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Quanterix is more favorable than Pacific Biosciences of California.
Institutional and Insider Ownership
45.7% of Quanterix shares are owned by institutional investors. Comparatively, 71.2% of Pacific Biosciences of California shares are owned by institutional investors. 31.6% of Quanterix shares are owned by company insiders. Comparatively, 13.4% of Pacific Biosciences of California shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Quanterix and Pacific Biosciences of California’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pacific Biosciences of California||-105.22%||-91.11%||-58.10%|
Quanterix beats Pacific Biosciences of California on 10 of the 13 factors compared between the two stocks.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. Quanterix Corporation has a collaboration agreement with DestiNA Genomics to focus on the development of a nucleic acid assay for direct detection and quantification of the liver toxicity biomarker microRNA-122. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.